The stories you’ve read the most in 2023 (so far)

From staff shortages to presidential candidates and the M&A outlook, here are our most-read stories from the first half of the year.

By PharmaVoice Staff • July 3, 2023

Intercept’s NASH retreat is the latest setback for a challenging liver disease

Intercept Pharmaceuticals has stepped out of the race to the first U.S. approved treatment for the complicated liver disease NASH, leaving room for other pharmas to get their foot in the door.

By Michael Gibney • June 27, 2023

Explore the Trendline➔

Rare diseases

As drug developers find promise in the rare diseases, deals and treatments are on the rise

By PharmaVoice staff

The spotlight is on accelerated approvals — now FDA could run a tighter ship

As the fallout of the Aduhelm approval continues, scrutiny of the speedier pathway has increased and the pressure is on to close a key gap in the regulation.

By Kelly Bilodeau • June 20, 2023

Shaking up pharma: Change that leaders would like to see

Industry execs give voice to the “game changers” they believe would have the greatest impact on the healthcare ecosystem for all.

By Taren Grom • June 16, 2023

How pharma execs are approaching drug pricing and other quandaries

From implementation of the Inflation Reduction Act, to the looming patent cliff and more, pharma leaders have a lot on their plates.

By Karissa Waddick • June 16, 2023

Why cancer could be the ideal realm for psychedelic treatments

The CEO of Sunstone Therapies said the results of a recent trial testing psilocybin in cancer patients with depression were “remarkable.”

By Meagan Parrish • June 9, 2023

FDA’s decentralized trials guidance leaves slate of fresh questions for industry

Recent FDA guidance aims to bolster DCT adoption but provides little clarity on the patchwork of telemedicine laws that pose an obstacle to the approach.

By Karissa Waddick • June 8, 2023

Yes, biopharma still has a reputation problem. These leaders are looking for solutions

Negative news is breaking down the public’s perception of the biopharma industry — but leaders around the industry have some ideas to fix it.

By Michael Gibney • June 8, 2023

A key to ‘winning’ in today’s market — and other trends pharma leaders are tracking

Healthcare pros share the market drivers they believe are having the biggest impact on the industry.

By Taren Grom • June 2, 2023

Lawmakers look to crack down on Big Pharma tax breaks

As lawmakers shine a light on Big Pharma tax cuts, the industry’s business moves are coming under attack from multiple angles. 

By Alexandra Pecci • May 31, 2023

3 FDA decisions that could be delayed if the U.S. defaults on its debt

If federal lawmakers don’t vote to raise the debt limit by early June, these FDA actions could be impacted.

By Karissa Waddick • May 30, 2023

From FTC to SCOTUS, Amgen’s woes are potential ‘game changers’ for the industry

The two institutional battles offer a glimpse into the tension between pharma innovation and regulation that could reverberate across the industry.

By Michael Gibney • May 25, 2023

Biden’s pick to lead the NIH faces an uphill battle

Pending Senate confirmation, NCI head Monica Bertagnolli will take the helm of the collection of research organizations as it faces increasing bipartisan scrutiny. 

By Karissa Waddick • May 18, 2023

Major regulatory changes are coming to pharma in the EU — and industry’s weighing in

The European Union published a long-awaited proposal that could bring sweeping changes to its pharma sector last month, but the legislative fight has only just begun.

By Karissa Waddick • May 16, 2023

Years into the pandemic, only a handful of clinical trials are targeting long COVID — here’s one of them

Scientists at Stanford are testing Pfizer’s Paxlovid on long COVID symptoms and their efforts could provide clues for other conditions.  

By Kelly Bilodeau • May 15, 2023

AbbVie’s Christopher Boone on RWE’s potential — and its ‘profound ethical dilemmas’

With decades of experience in public health, Boone is leveraging RWE to move the needle within clinical development.

By Taren Grom • May 10, 2023

3 key FDA approval trends this year

Although approvals are off to a slow start in oncology, the agency has been living in the fast lane for neurological disorders and more.

By Kelly Bilodeau • May 8, 2023

Insulin prices have dropped — will Civica still be a disrupter in the field?

The nonprofit generics maker still sees a need for low-cost insulin despite recent moves by major drugmakers to slash the prices of their popular products. 

By Karissa Waddick • May 8, 2023

Woman of the Week: Jazz Pharmaceuticals’ Neena Patil

Patil’s dual interests in healthcare and law are at the intersection of her C-suite role.

By Taren Grom • May 3, 2023

Taking your biotech global? Here’s how you can navigate cultural norms

What’s so different about doing pharma business in the U.K. versus Japan? One of Moderna’s top brass shares her tips for navigating choppy cultural waters.

By Alexandra Pecci • May 2, 2023

A physician’s perspective on health equity, diversity and inclusion

Dr. Preeti Parikh sees parallels between promoting health equity and current DE&I challenges in the workplace.

By Preeti Parikh, MD, Executive Medical Director, GoodRx • April 24, 2023

A new era of COVID innovation is here

With a $5 billion dollar infusion, a new White House program is helping catalyze development of next-gen treatments, from pan-coronavirus vaccines to enhanced antivirals. 

By Kelly Bilodeau • April 17, 2023

Patient influencers are here to stay — where are the regulations?

As social media health influencers enter the world of pharma advertising, experts warn that more guardrails are needed to protect the industry and patients.

By Karissa Waddick • April 17, 2023

Fighting vaccine hesitancy may require a new approach from pharma

The COVID-19 pandemic highlighted an ongoing problem of vaccine hesitancy undermining public health efforts. One way pharmas can help is to change the narrative.

By Michael Gibney • April 13, 2023

After working at Merck during the Vioxx scandal, this former sales rep is on a mission to fix the system

The founder and CEO for the Accreditation Council for Medical Affairs is increasing accountability in pharma by emphasizing training, standards and ethics in medical affairs.

By Alexandra Pecci • April 11, 2023